Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | KIF5B | P33176 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812508 | 0.89 | ERBB2 (0.50) | EGFRERBB2RETKIF5BKDR | |
| SCHEMBL3808108 | 0.88 | EGFR (0.53) | EGFRERBB2RETKIF5BKDR | |
| SCHEMBL3810503 | 0.88 | ERBB2 (0.57) | EGFRERBB2KCNH2 | |
| SCHEMBL3817555 | 0.82 | KDR (0.49) | EGFRERBB2RETDYRK1ADYRK1B | |
| SCHEMBL3808303 | 0.80 | ERBB2 (0.45) | EGFRERBB2KDRKCNH2 | |
| SCHEMBL3810411 | 0.79 | DYRK1A (0.54) | EGFRRETDYRK1ADYRK1BKIF5B | |
| SCHEMBL4480933 | 0.79 | ERBB2 (0.55) | EGFRERBB2KDRKCNH2 | |
| SCHEMBL4480016 | 0.78 | EGFR (0.48) | EGFRERBB2RETKIF5BKDR | |
| SCHEMBL4485031 | 0.78 | ERBB2 (0.62) | EGFRERBB2KCNH2 | |
| SCHEMBL3811494 | 0.78 | EGFR (0.52) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631292-B1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070149546-A1 | 4-Anilino-quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| EP-1631292-A1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astra Zeneca AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004093880-A1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149546-A1 | 4-Anilino-quinazoline derivatives as antiproliferative agents | ABL1, ERBB2, ERBB4 | EGFR 10/4885ERBB2 2/4885RET 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.